Tozaride (Rhenium (Re) 188 P2045) / Andarix - LARVOL DELTA

L2 β-lactamase contributes to ceftolozane-tazobactam resistance in Pseudomonas aeruginosa. (PubMed, Antimicrob Agents Chemother) - "The prevalence of non-susceptibility to ceftolozane-tazobactam (C/T) among Pseudomonas aeruginosa remains low, but novel mechanisms of C/T resistance are of concern. Interestingly, disruption of the gene blaL2 but not the truncated ampRL2 in PS2045 led to a decrease in C/T MIC. Thus, we report a novel mechanism of C/T resistance in P. aeruginosa partially mediated by an L2 β-lactamase independently of its canonical regulator, AmpRL2."

Journal

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China. (PubMed, EClinicalMedicine) - P2 | "Patients with resectable stage II-IIIB EGFR (AJCC 8th edition) mutant NSCLC were enroled and received neoadjuvant sintilimab (200 mg) plus carboplatin (area under the curve 5) and nab-paclitaxel (260 mg/m2) for 3 cycles. Patients in stage II cohort received adjuvant osimertinib for up to 2 years while observation for stage I cohort...provided PD-1 regimen (sintilimab), participant compensation and insurance. This work was supported by National Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China National High-Level Talents Special Support Program, National Natural Science Foundation of China Major Joint Project on Key scientific issues of lung Cancer, Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer, Integrated Project of Major Research Plan of National Natural Science Foundation of China, National Health Commission Medical and Health Technology..."

IO biomarker • Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • RB1 • RBM10

Theranostic clinical study with 188 Re P2045 in lung cancer expressing SSTR and well differentiated Neuroendocrine tumours (TAT-Alpha 2026) - "No adverse events or signs of toxicity were reported by patients in either the imaging or treatment group. Conclusion This trial demonstrates that Rhenium 188 Re P2045 can be used safely and efficaciously to both identify and treat patients with lung cancers and neuroendocrine tumors overexpressing SSTR."

Clinical • Lung Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • SSTR • SSTR2

A novel mechanism of ceftolozane-tazobactam resistance in Pseudomonas aeruginosa mediated by L2 β-lactamase. (PubMed, bioRxiv) - "The prevalance of non-susceptibility to ceftolozane-tazobactam (C/T) among Pseudomonas aeruginosa remains low but novel mechanisms of C/T resistance are of concern. Interestingly, disruption of the gene bla L2 but not the truncated ampR L2 in PS2045 led to a significant decrease in C/T MIC. Thus, we report a novel mechanism of C/T resistance in P. aeruginosa mediated by an L2 β-lactamase independently of its canonical regulator AmpR L2 ."

Journal

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). (PubMed, Cell Rep Med) - "Here, we report interim results of a Simon's two-stage design, phase 2 trial using neoadjuvant sintilimab with carboplatin and nab-paclitaxel in resectable EGFR-mutant NSCLC. Informed circulating tumor DNA (ctDNA) detection in EGFR-mutant NSCLC could help identify patients nonresponsive to neoadjuvant immunochemotherapy. These findings provide supportive data for the utilization of neoadjuvant immunochemotherapy and insight into immune resistance in EGFR-mutant NSCLC."

IO biomarker • Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CCR8 • CXCL13 • EGFR

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Andarix Pharmaceuticals | Unknown status ➔ Recruiting | Trial completion date: Apr 2020 ➔ Apr 2025

Enrollment open • Trial completion date • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Sydney skin cancer patients join the EPIC-Skin study as they undergo first treatments with OncoBeta's Rhenium-SCT (PRNewswire) - "OncoBeta® GmbH has announced its first Sydney-based patients were treated with Rhenium-SCT® as part of the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer [NMSC])....These patients were treated on 8 April and are now part of 210 adults participating in the international study that will follow their progress over the next 24 months."

Trial status • Non-melanoma Skin Cancer • Oncology • Skin Cancer

"#AndarixPharmaceuticals Awarded Trademark for #Tozaride by the US #Patent and Trademark Office https://t.co/RrmjLxsDD8" (,@1stOncology)